CRBU
Caribou Biosciences, Inc.1.6900
-0.0200-1.17%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
157.96MP/E (TTM)
-Basic EPS (TTM)
-1.70Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Caribou narrowed Q3 losses to $27.5M from $34.7M y/y, with licensing revenue ticking up 9% to $2.2M while R&D expenses dropped 26% to $22.4M on lower external clinical costs and post-restructuring workforce cuts. Operating loss improved to $29.4M from $38.2M y/y, though YTD net loss widened to $121.6M from $113.6M due to $12.2M asset impairments and $9.2M equity investment write-off, offset by lower opex. Cash burn slowed, with $159.2M in cash and marketable securities at quarter-end funding operations at least 12 more months. Restructuring complete. Nasdaq bid price compliance remains a risk.
8-K
Strong CAR-T data, $159M cash
Caribou Biosciences unveiled strong Q3 2025 data for allogeneic CAR-T therapies vispa-cel and CB-011, matching autologous efficacy with outpatient-friendly safety. Vispa-cel hit 82% ORR and 64% CR in confirmatory LBCL cohort; CB-011 showed 92% ORR in MM dose escalation. Cash stands at $159.2M, funding operations into 2H 2027. Data propel pivotal trials forward.
8-K
Robust CAR-T phase 1 data released
Caribou Biosciences unveiled strong phase 1 data for allogeneic CAR-T vispa-cel in r/r LBCL, posting 82% ORR and 64% CR in the 22-patient confirmatory cohort with 4+ HLA matching, alongside 51% 12-month PFS. CB-011 in r/r MM hit 92% ORR and 75% CR in 12 BCMA-naïve patients at the 450x10^6 dose. Cash sits at ~$159M; vispa-cel eyes FDA-guided phase 3 in 2L LBCL. Data may evolve.
8-K
Q2 results: cash to 2027
Caribou Biosciences reported Q2 2025 results, with cash at $183.9M funding operations into H2 2027, down from $249.4M year-end. R&D expenses dropped to $27.7M from $35.5M after pipeline prioritization and workforce cuts, though $21.3M non-cash impairments drove GAAP net loss to $54.1M. CB-010 and CB-011 enrollment completed; data due H2 2025. Cash burn eased.
10-Q
Q2 FY2025 results
Caribou's Q2 revenue dipped 23% y/y to $2.7M from licensing deals, yet R&D expenses fell 22% to $27.7M amid pipeline cuts and 32% headcount trim. Operating loss widened to $47.6M on $12.2M impairments and $9.2M equity writedown, pushing net loss to $54.1M ($0.58/share, confirmed vs 93M shares). Cash burn eased; $184M liquidity funds ops 12+ months. Strategic focus sharpened on CB-010, CB-011. Nasdaq bid price compliance recently regained.
ALLO
Allogene Therapeutics, Inc.
1.54+0.07
CABA
Cabaletta Bio, Inc.
2.39+0.00
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CLLS
Cellectis S.A.
4.06-0.73
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
MBIO
Mustang Bio, Inc.
1.07-0.06
TCRX
TScan Therapeutics, Inc.
0.95-0.01